Division of Cardiothoracic Surgery, Department of Surgery, Southern Illinois University School of Medicine, 701 N. First Street D252, Springfield, IL 62794-9679, USA.
Thorac Surg Clin. 2021 May;31(2):189-201. doi: 10.1016/j.thorsurg.2021.01.002.
Endobronchial valve therapy has evolved over the past decade, with demonstration of significant improvements in pulmonary function, 6-minute walk distance, and quality of life in patients with end-stage chronic obstructive lung disease. Appropriate patient selection is crucial, with identification of the most diseased lobe and of a target lobe with minimal to no collateral ventilation. Endobronchial valve therapy typically is utilized in patients with heterogeneous disease but may be indicated in select patients with homogeneous disease. Morbidity and mortality have been lower than historically reported with lung volume reduction surgery, but complications related to pneumothoraces remain a challenge.
支气管内阀治疗在过去十年中不断发展,在终末期慢性阻塞性肺疾病患者中,展示了在肺功能、6 分钟步行距离和生活质量方面的显著改善。适当的患者选择至关重要,需要确定最患病的肺叶和目标肺叶,并且该肺叶的分流量最小或没有。支气管内阀治疗通常用于异质性疾病患者,但在某些同质疾病患者中也可能适用。发病率和死亡率低于肺减容手术的历史报告,但与气胸相关的并发症仍然是一个挑战。